Cannabis seeds contain the genetic blueprint that determines plant structure, cannabinoid levels, terpene profiles, and resilience. As cultivation evolves globally, understanding genetics and choosing stable seed sources has become essential for growers seeking consistent, high-quality harvests.
Technion Israel Institute of Technology, Prof. Dedi Meiri is redefining cannabis science through molecular research. From cancer pathways to the endocannabinoid system, his lab maps how specific cannabinoid profiles interact with disease, bringing precision, data, and clarity to medical cannabis.
New UK research adds to growing evidence that medical cannabis may help people living with fibromyalgia manage chronic pain, anxiety, sleep issues, and overall quality of life. The large real-world study tracked patient outcomes over 18 months using cannabis-based treatments.
The U.S. decision to reschedule cannabis to Schedule III signals federal recognition of medical value. Industry voices examine 280E tax relief, research access, patient impact, and the unresolved limits of reform.
Four 20 Pharma CEO Torsten Greif is redefining medical cannabis in Germany — from EU-GMP supply chains and certified vapes to a historic soccer sponsorship that put plant medicine on the global stage.
At Expopharm Düsseldorf, Honeysuckle spoke with Remexian Pharma leaders Stefan Adomeit and Francesco Baganz about Germany’s rapidly evolving medical market—where patient demand, shrinking margins, and cross-border consolidation are reshaping the future.
If the U.S. cannabis industry shifts into a pharmaceutical model, what happens to the culture built on community, creativity, and flavor? We explore how pharma could reshape weed—and why preserving the experience matters more than ever.
At Expopharm 2025 in Düsseldorf, Europe’s largest pharma trade fair, cannabis was given a dedicated spotlight. The focus on plant-based therapies signaled their growing role in healthcare — once fringe, now central to Europe’s pharmaceutical conversation.
Leaders including Sasho Stefanoski and Jamie L. Pearson joined the Medical Resource Association, Inc. panel, exploring global cannabis lessons, local opportunities, and the need for patient-centered systems built on trust, sustainability, and innovation.
Science in the City International returns to Bordeaux on Sept 11–12, 2025, with global leaders in cannabis science, medicine, and industry. Featuring voices like PHCANN CEO Sasho Stefanoski, the summit blends education, networking, and French elegance at La Cité du Vin.
Enua CEO Albert Schwarzmeier has scaled the German company from 15 to 55 employees and built strong pharmacy partnerships, making it a top-three medical cannabis distributor. With expansion into the UK and Poland ahead, enua is shaping Europe’s fast-growing €2B cannabis market.
enua CEO Albert Schwarzmeier shares the Greek roots of the company’s name and its mission to go beyond patient care — aiming to change society for the better. Stay tuned for the full interview coming soon to Honeysuckle Media.
A new report from BayMedica shows THCV-infused products yielding 23.7% higher margins, CBC’s untapped potential, and gummies leading rare cannabinoid delivery—signaling major growth opportunities for cannabis brands and formulators.
Slovenia takes a bold leap in cannabis reform, approving one of the world’s most progressive medical marijuana laws while introducing a new proposal to allow limited home cultivation and possession for adults.
A new Bloomwell survey reveals 42% of German cannabis patients would return to illicit sources if digital access is restricted. With patient numbers up 1100% since reclassification, leaders warn that political rollbacks could reverse medical progress.
